Condition: Kidney Disease, Chronic · Diabetes · Dialysis · Sponsor: Unity Health Toronto
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
This description comes directly from the study's public registry record.
Ron Wald, MD · (416) 867-3703 · ron.wald@unityhealth.to
Kevin Yau, MD · Kevin.Yau@uhn.ca
Always discuss trial participation with your own doctor first.
| Unity Health Toronto | Toronto, Ontario, Canada | Recruiting |
| Unity Health Toronto | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07017270